MCL1 and hematopoietic and lymphoid system neoplasm: It seems that miR-29 plays a vital role in blood cancers by modulating T-cell leukemia/lymphoma protein 1 (TCL1), myeloid cell leukemia 1 (MCL1), and DNA-methyltransferase enzymes [92].